Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay

[News]

The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad's molecular residual disease (MRD) assay.

More... (https://www.news-medical.net/news/20250107/Myriad-Genetics-and-MD-Anderson-partner-to-evaluate-molecular-residual-disease-assay.aspx)